AU2018358582B2 - Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer - Google Patents
Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer Download PDFInfo
- Publication number
- AU2018358582B2 AU2018358582B2 AU2018358582A AU2018358582A AU2018358582B2 AU 2018358582 B2 AU2018358582 B2 AU 2018358582B2 AU 2018358582 A AU2018358582 A AU 2018358582A AU 2018358582 A AU2018358582 A AU 2018358582A AU 2018358582 B2 AU2018358582 B2 AU 2018358582B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- biindolinylidene
- imino
- ethoxy
- flt3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170144142 | 2017-10-31 | ||
| KR10-2017-0144142 | 2017-10-31 | ||
| PCT/KR2018/013051 WO2019088677A1 (ko) | 2017-10-31 | 2018-10-30 | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018358582A1 AU2018358582A1 (en) | 2020-05-07 |
| AU2018358582B2 true AU2018358582B2 (en) | 2021-06-10 |
Family
ID=66333236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018358582A Active AU2018358582B2 (en) | 2017-10-31 | 2018-10-30 | Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11370779B2 (enExample) |
| EP (1) | EP3705474A4 (enExample) |
| JP (1) | JP7005779B2 (enExample) |
| KR (1) | KR102247795B1 (enExample) |
| CN (1) | CN111542513A (enExample) |
| AU (1) | AU2018358582B2 (enExample) |
| BR (1) | BR112020008499A2 (enExample) |
| CA (1) | CA3080900C (enExample) |
| MX (1) | MX2020004374A (enExample) |
| PH (1) | PH12020550491A1 (enExample) |
| RU (1) | RU2763346C2 (enExample) |
| WO (1) | WO2019088677A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12021552551A1 (en) | 2019-04-26 | 2022-06-20 | Unilever Ip Holdings B V | Hair conditioning composition |
| CN110305056A (zh) * | 2019-05-22 | 2019-10-08 | 西北大学 | 靛玉红新衍生物及其药用用途 |
| WO2021090172A1 (en) * | 2019-11-04 | 2021-05-14 | Ck Biotechnology Co. | Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof |
| KR102296440B1 (ko) * | 2019-12-06 | 2021-09-02 | 주식회사 펠레메드 | 신규한 인디루빈 유도체 및 이의 용도 |
| KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
| KR102325607B1 (ko) | 2020-02-20 | 2021-11-12 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR20210106155A (ko) | 2020-02-20 | 2021-08-30 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR102278176B1 (ko) | 2020-02-20 | 2021-07-16 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| KR102744517B1 (ko) * | 2022-02-14 | 2024-12-19 | 주식회사 펠레메드 | 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도 |
| EP4674839A1 (en) * | 2023-02-28 | 2026-01-07 | CK Regeon Inc. | Novel indoline derivative and use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000061555A1 (en) * | 1999-04-12 | 2000-10-19 | Gerhard Eisenbrand | Indigoid bisindole derivatives |
| WO2011096676A2 (en) * | 2010-02-05 | 2011-08-11 | Anygen Co., Ltd. | Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| WO2013142817A2 (en) * | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| WO2014153023A1 (en) * | 2013-03-14 | 2014-09-25 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) * | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| JP5448455B2 (ja) | 2005-12-23 | 2014-03-19 | サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク （セ エン エール エス） | 新規３’−，７−置換インジルビンおよびそれらの適用 |
| EP2149553B1 (en) | 2008-08-01 | 2011-10-19 | Centre National de la Recherche Scientifique | 3', 6-substituted indirubins and their biological applications |
| US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
-
2018
- 2018-10-30 KR KR1020180131294A patent/KR102247795B1/ko active Active
- 2018-10-30 CA CA3080900A patent/CA3080900C/en active Active
- 2018-10-30 EP EP18873750.6A patent/EP3705474A4/en active Pending
- 2018-10-30 JP JP2020543443A patent/JP7005779B2/ja active Active
- 2018-10-30 RU RU2020115581A patent/RU2763346C2/ru active
- 2018-10-30 AU AU2018358582A patent/AU2018358582B2/en active Active
- 2018-10-30 WO PCT/KR2018/013051 patent/WO2019088677A1/ko not_active Ceased
- 2018-10-30 BR BR112020008499-9A patent/BR112020008499A2/pt not_active IP Right Cessation
- 2018-10-30 CN CN201880084849.8A patent/CN111542513A/zh active Pending
- 2018-10-30 MX MX2020004374A patent/MX2020004374A/es unknown
-
2020
- 2020-04-24 PH PH12020550491A patent/PH12020550491A1/en unknown
- 2020-04-30 US US16/862,923 patent/US11370779B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000061555A1 (en) * | 1999-04-12 | 2000-10-19 | Gerhard Eisenbrand | Indigoid bisindole derivatives |
| WO2011096676A2 (en) * | 2010-02-05 | 2011-08-11 | Anygen Co., Ltd. | Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| WO2013142817A2 (en) * | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| WO2014153023A1 (en) * | 2013-03-14 | 2014-09-25 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) * | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
Non-Patent Citations (7)
| Title |
|---|
| Bioorganic & Medicinal Chemistry Letters, 2010, Vol. 20, No. 6, pages 2033-2037 * |
| Bioorganic & Medicinal Chemistry, 2017, Vol. 25, No. 17, pages 4665-4676 * |
| CAS Registry Number: 1591767-01-9; STN Entry date 28 April 2014 * |
| Chemistry & Biodiversity, 2012, Vol. 9, No. 10, pages 2175-2185. * |
| Journal of Medicinal Chemistry, 2017, Vol. 60, No. 12, pages 4949-4962. * |
| Leukemia Research, 2013, Vol. 37, No. 4, pages 427-433. * |
| Molecular Oncology, 2012, Vol. 6, No. 3, pages 276-283. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018358582A1 (en) | 2020-05-07 |
| BR112020008499A2 (pt) | 2020-10-20 |
| PH12020550491A1 (en) | 2021-01-11 |
| WO2019088677A1 (ko) | 2019-05-09 |
| CA3080900C (en) | 2022-10-25 |
| KR102247795B9 (ko) | 2023-04-12 |
| US20200270229A1 (en) | 2020-08-27 |
| CA3080900A1 (en) | 2019-05-09 |
| EP3705474A1 (en) | 2020-09-09 |
| EP3705474A4 (en) | 2021-06-09 |
| KR20190049584A (ko) | 2019-05-09 |
| MX2020004374A (es) | 2020-11-11 |
| RU2020115581A3 (enExample) | 2021-12-02 |
| KR102247795B1 (ko) | 2021-05-04 |
| RU2020115581A (ru) | 2021-12-02 |
| JP2021501208A (ja) | 2021-01-14 |
| RU2763346C2 (ru) | 2021-12-28 |
| CN111542513A (zh) | 2020-08-14 |
| JP7005779B2 (ja) | 2022-02-10 |
| US11370779B2 (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3080900C (en) | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | |
| US6403588B1 (en) | Imidazopyridine derivatives | |
| TW200307535A (en) | Therapeutic agent for cancer | |
| WO2014165090A1 (en) | Compounds for the treatment of tuberculosis | |
| JPH08269059A (ja) | 新規のピリド［３，２−ｅ］ピラジノン及びその製法、これを含有する抗喘息及び抗アレルギー作用を有する薬剤及びこの薬剤の製法 | |
| HUE027534T2 (en) | Notch pathway inhibitory compound | |
| AU2019218187B2 (en) | Dioxinoquinoline compounds, preparation method and uses thereof | |
| WO2022232391A1 (en) | Phthalimido cereblon complex binders and transcription factor degraders and methods of use | |
| WO2013170758A1 (zh) | 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用 | |
| JP2019512459A (ja) | ７員環化合物、その調製方法、その医薬組成物、およびその使用 | |
| JP2025503139A (ja) | 固形腫瘍の治療のためのユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤 | |
| WO2019029629A1 (en) | SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS | |
| EA037876B1 (ru) | Соединение в виде аминозамещенного шестичленного гетероциклического кольца с гетероатомом азота, его получение и использование | |
| KR20210047850A (ko) | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 | |
| US10173995B2 (en) | Pyridine compounds used as PI3 kinase inhibitors | |
| AU757611B2 (en) | Optically active pyrrolopyridazine compounds | |
| KR20220114569A (ko) | 항암 화합물로서 cullin 3 어댑터 kbtbd4의 모듈레이터 | |
| WO2018204286A1 (en) | An anti-cancer stemness drug | |
| WO2019001307A1 (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
| CN109134433B (zh) | 一种抑制rock的化合物及其应用 | |
| US20250059139A1 (en) | Compounds for treatment of cancer | |
| JPS625968A (ja) | 新規ｎ置換３，４―ジヒドロピリミジン誘導体および血管拡張剤 | |
| KR20190063746A (ko) | p34 단백질 및 NEDD4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도 | |
| KR101995533B1 (ko) | [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| CN121985947A (zh) | 用于治疗银屑病、特应性皮炎或鱼鳞病的trex2的1,2,4-三唑-3-硫酮抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |